Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine - Tập 380 Số 4 - Trang 347-357 - 2019
Stephen D. Wiviott1, Lawrence A. Leiter2, Marc P. Bonaca1, Ofri Mosenzon2, Eri Kato3, Avivit Cahn2, Michael G. Silverman4, Thomas A. Zelniker1, Julia Kuder1, Sabina A. Murphy1, Deepak L. Bhatt1, Darren K. McGuire5, John Wilding6, Christian T. Ruff1, Ingrid Gause‐Nilsson, Martin Fredriksson7, Peter A. Johansson7, AM Langkilde7, Marc S. Sabatine1
1Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital
2Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem
3Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
4Cardiology Division, Massachusetts General Hospital
5Division of Cardiology, University of Texas Southwestern Medical Center, Dallas
6Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom
7AstraZeneca Gothenburg, Mölndal, Sweden

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1016/j.diabres.2017.03.024

10.1161/CIR.0b013e3182009701

10.1001/jama.298.7.765

10.1016/j.jchf.2016.08.001

10.1056/NEJM199910073411506

Yancy CW, 2017, Circulation, 136, e137, 10.1161/CIR.0000000000000509

10.1016/j.jacc.2013.05.019

10.2337/dc18-S009

10.2337/dc18-S008

10.2337/db07-1472

10.1038/clpt.2008.250

10.1007/s40265-014-0324-3

10.1056/NEJMoa1504720

10.1056/NEJMoa1611925

10.1161/CIRCULATIONAHA.117.032038

10.1016/S2213-8587(18)30141-4

10.1016/S2213-8587(17)30182-1

10.1056/NEJMoa1515920

10.1016/j.ahj.2018.01.012

10.1111/dom.13217

10.7326/0003-4819-150-9-200905050-00006

10.1161/CIRCULATIONAHA.117.033502

10.1002/sim.3513

10.1093/eurheartj/ehw128

10.4158/CS-2017-0153

10.1136/jnnp-2016-314704

10.1111/dom.13255

10.1089/dia.2018.0246

10.1093/eurheartj/ehv728

10.1002/ejhf.633

10.1016/j.kint.2017.12.027

10.1161/CIRCULATIONAHA.118.035083

10.1111/1753-0407.12616

10.21037/atm.2016.10.36

10.1056/NEJMra1510061